Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.

Zhou Q, Ye Z, Ruan Z, Zeng S.

J Ethnopharmacol. 2013 Apr 19;146(3):744-9. doi: 10.1016/j.jep.2013.01.037. Epub 2013 Feb 17.

PMID:
23422332
2.

Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.

Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, Penzak SR.

J Clin Pharmacol. 2012 Jun;52(6):932-9. doi: 10.1177/0091270011407194. Epub 2011 Jun 6.

3.

Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.

Kim KA, Park PW, Park JY.

Eur J Clin Pharmacol. 2009 Jun;65(6):609-14. doi: 10.1007/s00228-009-0627-6. Epub 2009 Feb 17.

PMID:
19221726
4.

Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.

Kharasch ED, Walker A, Hoffer C, Sheffels P.

J Clin Pharmacol. 2005 Jan;45(1):79-88.

PMID:
15601808
5.

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.

Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG.

Clin Pharmacol Ther. 2005 Aug;78(2):191-201.

PMID:
16084853
6.

A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.

Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG.

Clin Pharmacol Ther. 2004 Nov;76(5):418-27.

PMID:
15536457
7.
8.

Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.

Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T.

Xenobiotica. 2010 Nov;40(11):782-9. doi: 10.3109/00498254.2010.515318.

PMID:
20839930
9.

Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Shimizu M, Uno T, Sugawara K, Tateishi T.

Br J Clin Pharmacol. 2006 May;61(5):538-44.

10.

Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.

Liu S, Beringer PM, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B.

J Clin Pharmacol. 2008 Aug;48(8):957-65. doi: 10.1177/0091270008319707. Epub 2008 May 29.

PMID:
18511651
11.

The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.

Tateishi T, Miura M, Suzuki T, Uno T.

Br J Clin Pharmacol. 2008 May;65(5):693-700. doi: 10.1111/j.1365-2125.2008.03116.x. Epub 2008 Feb 20.

12.
13.

Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.

Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T.

Br J Clin Pharmacol. 2009 May;67(5):535-40. doi: 10.1111/j.1365-2125.2009.03396.x. Epub 2009 Jan 23.

14.

Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.

Kitamura Y, Koto H, Matsuura S, Kawabata T, Tsuchiya H, Kusuhara H, Tsujimoto H, Sugiyama Y.

Drug Metab Dispos. 2008 May;36(5):807-10. doi: 10.1124/dmd.107.017624. Epub 2008 Feb 25.

15.

Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.

Kim KA, Park JY.

Eur J Clin Pharmacol. 2010 Jul;66(7):721-5. doi: 10.1007/s00228-010-0797-2. Epub 2010 Mar 20.

PMID:
20306185
16.

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.

Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.

Clin Pharmacol Ther. 2006 Mar;79(3):218-30. Epub 2006 Feb 7.

PMID:
16513446
17.

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF.

Br J Clin Pharmacol. 2002 May;53(5):526-34.

18.

Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.

Uno T, Shimizu M, Sugawara K, Tateishi T.

Drug Metab Dispos. 2006 Nov;34(11):1875-9. Epub 2006 Aug 23.

19.

Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.

Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V.

Clin Ther. 2001 Mar;23(3):451-66.

PMID:
11318079
20.

Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.

Akamine Y, Miura M, Yasui-Furukori N, Ieiri I, Uno T.

J Clin Pharm Ther. 2015 Feb;40(1):98-103. doi: 10.1111/jcpt.12213. Epub 2014 Sep 27.

PMID:
25263393
Items per page

Supplemental Content

Write to the Help Desk